Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis

BACKGROUND: Interstitial pneumonia (IP) is one of the most common and poor prognostic comorbidities in patients with small cell lung cancer (SCLC). The pharmacotherapy for SCLC occasionally induces fatal acute exacerbation of comorbid IP, especially in patients with idiopathic pulmonary fibrosis (IP...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Satoshi, Ogura, Takashi, Kato, Terufumi, Kenmotsu, Hirotsugu, Iwasawa, Tae, Misumi, Toshihiro, Yamanaka, Takeharu, Okamoto, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238300/
https://www.ncbi.nlm.nih.gov/pubmed/32489433
http://dx.doi.org/10.1177/1758835920923431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238300/
https://www.ncbi.nlm.nih.gov/pubmed/32489433
http://dx.doi.org/10.1177/1758835920923431

Ejemplares similares